Treatment of Parkinson's disease in Japan

Parkinsonism and Related Disorders

Volumn 7, Issue 1, 2000, Pages 71-77

  Kondo, T ^a  

^a WAKAYAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

DA agonist; Levodopa; Motor fluctuations; Parkinson's disease; Treatment

Indexed keywords

DOPAMINE; DOPAMINE RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA;

DRUG EFFICACY; DRUG RECEPTOR BINDING; DYSKINESIA; HUMAN; JAPAN; ON OFF PHENOMENON; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; SCORING SYSTEM;

EID: 0033805756     PISSN: 13538020     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1353-8020(00)00043-2     Document Type: Article

References (29)

1. Melamed E., Bitton V., Zelig O. Delayed onset of responses to single doses of L-dopa in parkinsonian fluctuators on long-term L-dopa therapy. Clin Neuropharmacol. 9:1986;182-188.
2. Melamed E., Bitton V., Zelig O. Episodic unresponsiveness to single doses of L-dopa in parkinsonian fluctuators. Neurology. 36:1986;100-103.
3. Muenter M.D., Tyce G.M. L-dopa therapy of Parkinson's disease: plasma L-dopa concentration, therapeutic response, and side effects. Mayo Clin Proc. 46:1971;231-239.
4. Muenter M.D., Sharpless N.S., Tyce G.M., Darley F.L. Patterns of dystonia ("I-D-I" and "D-I-D") in response to L-dopa therapy for Parkinson's disease. Mayo Clin Proc. 52:1977;163-174.
5. Narabayashi H. Clinical analysis of akinesia. J Neural Transm Suppl. 16:1980;129-136.
6. Nakanishi T., Kowa H., Mizuno Y., Yanagisawa N. The clinical evaluation of BH-T 920 (talipexole hydrochloride) in Parkinson's disease - a multi-center double-blind comparative study vs. bromocriptine mesilate. Clin Eval. 21:1993;59-110.
7. Narabayashi H., Kondo T. Results of double-blind study of L-threo-DOPS in parkinsonism. Fahn S., Marsden C.D., Goldstein M., Calne D.B. Recent development in Parkinson's disease II. 1987;279-291 Macmillan Healthcare Information, New Jersey.
8. Ogawa N., Kanazawa I., Kowa H., Kuno S., Mizuno Y., Tashiro K., Yanagisawa N. Nationwide multicenter prospective study on the long-term effects of bromocriptine for Parkinson's disease. Final report of a ten-year follow-up. Eur Neurol. 38:(2):1997;37-49.
9. Rinne U.K., Bracco F., Chouza C., Dupont E., Gershanik O., Marti Masso J.F., Montastruc J.L., Marsden C.D. Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. The PKDS009 Study Group. Drugs. 55:(1):1998;23-30.
10. Pearce R.K., Banerji T., Jenner P., Marsden C.D. De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset. Mov Disord. 13:1998;234-241.
11. Takahashi S., Tohgi H., Yonezawa H., Obara S., Yamazaki E. The effect of trihexyphenidyl, an anticholinergic agent, on regional cerebral blood flow and oxygen metabolism in patients with Parkinson's disease. J Neurol Sci. 167:1999;56-61.
12. Kostic V., Przedborski S., Flaster E., Sternic N. Early development of levodopa-induced dyskinesias and response fluctuations in young-onset Parkinson's disease. Neurology. 41:1991;202-205.
13. Yokochi M., Narabayashi H., Iizuka R., Nagatsu T. Juvenile parkinsonism - some clinical, pharmacological, and neuropathological aspects. Adv Neurol. 40:1984;407-413.
14. Olanow C.W., Koller W.C. An algorithm (decision tree) for the management of Parkinson's disease: treatment guidelines. Neurology. 50:(3):1998;51-57.
15. Mouradian M.M., Juncos J.L., Fabbrini G., Schlegel J., Bartko J.J., Chase T. Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms. Part II. Ann Neurol. 24:1988;372-378.
16. Chase T.N. The significance of continuous dopaminergic stimulation in the treatment of Parkinson's disease. Drugs. 55:(1):1998;1-9.
17. Yokochi M., Kondo T., Hirayama K., Narabayashi H., Kureha I. Comparative studies of L-DOPA alone and combination with a peripheral DOPA decarboxylase inhibitor, benserazide-HCl, on Parkinson's disease. Part II. Pharmacokinetic study. No To Shinkei. 31:1979;339-348.
18. Murata M., Mizusawa H., Yamanouchi H., Kanazawa I. Chronic levodopa therapy enhances dopa absorption: contribution to wearing-off. J Neural Transm. 103:1996;1177-1185.
19. Kaseda S., Nomoto M., Iwata S. Effect of selegiline on dopamine concentration in the striatum of a primate. Brain Res. 815:1999;44-50.
20. Przuntek H., Conrad B., Dichgans J., Kraus P.H., Krauseneck P., Pergande G., Rinne U., Schimrigk K., Schnitker J., Vogel H.P. SELEDO: a 5-year long-term trial on the effect of selegiline in early parkinsonian patients treated with levodopa. Eur J Neurol. 6:1999;141-150.
21. Sivertsen B., Dupont E., Mikkelsen B., Mogensen P., Rasmussen C., Boesen F., Heinonen E. Selegiline and levodopa in early or moderately advanced Parkinson's disease: a double-blind controlled short- and long-term study. Acta Neurol Scand Suppl. 126:1989;147-152.
22. Myllyla V.V., Sotaniemi K.A., Hakulinen P., Maki-Ikola O., Heinonen E.H. Selegiline as the primary treatment of Parkinson's disease-a long-term double-blind study. Acta Neurol Scand. 95:1997;211-218.
23. Facca A., Sanchez-Ramos J. High-dose pergolide monotherapy in the treatment of severe levodopa-induced dyskinesias. Mov Disord. 11:1996;327-329.
24. Schwarz J., Scheidtmann K., Trenkwalder C. Improvement of motor fluctuations in patients with Parkinson's disease following treatment with high doses of pergolide and cessation of levodopa. Eur Neurol. 37:1997;236-238.
25. Markstein R., Herrling P.L. The effect of bromocriptine on rat striatal adenylate cyclase and rat brain monoamine metabolism. J Neurochem. 31:1978;1163-1172.
26. Melamed E., Hefti F. Mechanism of action of short- and long-term L-DOPA treatment in parkinsonism: role of the surviving nigrostriatal dopaminergic neurons. Adv Neurol. 40:1984;149-157.
27. Fuller R.W., Clemens J.A. Pergolide: a dopamine agonist at both D1 and D2 receptors. Life Sci. 49:1991;925-930.
28. Nutt J.G., Woodward W.R. Levodopa pharmacokinetics and pharmacodynamics in fluctuating parkinsonian patients. Neurology. 36:1986;739-744.
29. Kulisevsky J., Lopez-Villegas D., Garcia-Sanchez C., Barbanoj M., Gironell A., Pascual-Sedano B. A six-month study of pergolide and levodopa in de novo Parkinson's disease patients. Clin Neuropharmacol. 21:1998;358-362.